Initiate a first-in-humans Phase 1 study of UNI-494

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 31 Mar 2022
Due: 30 Sep 2022
Checked: 1 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“The Company plans to initiate a first-in-humans Phase 1 study of UNI-494 in the third quarter of 2022.”

SourceUnicycive Therapeutics, Inc. Form 8-K press release, 2022-03-31
FilingSEC filing index
Deadline as statedin the third quarter of 2022
Deadline used30 Sep 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2022-UNCY-002768
Cite as https://keptindex.org/c/KI-C-2022-UNCY-002768/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company did not initiate the Phase 1 study by the third quarter of 2022; filings indicate the Clinical Trial Application was submitted in December 2022.

A
Unicycive Therapeutics, Inc. 10-K filed 2023-03-31 Regulatory filing · published 31 Mar 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint dc3a9c71d0b1
“submitted a Clinical Trial Application (CTA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1 study in healthy volunteers in the United Kingdom in December 2022.” ✓ confirmed on the page

Market reaction: the shares moved +14.7% against the S&P 500 over the three sessions around the disclosure (30 Mar 2023 to 4 Apr 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +92 days
2 versions

Version 1 · original · stated 31 Mar 2022

Deadline 30 Sep 2022 (“in the third quarter of 2022”) · wording expected
Version 2 · stated 12 May 2022

Deadline 31 Dec 2022 (“in the second half of 2022”) · wording expected

“Company plans to initiate a first-in-humans Phase 1 study of UNI-494 in the second half of 2022.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 1 study of UNI-494
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.